Heart Institute and Department of Imaging, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
J Nucl Med. 2012 Apr;53(4):575-83. doi: 10.2967/jnumed.111.097550. Epub 2012 Mar 14.
Whether (18)F-FDG PET can detect inflammation in the coronary arteries remains controversial. We examined (18)F-FDG uptake at the culprit sites of acute myocardial infarction (AMI) after percutaneous coronary stenting (PCS) by coregistering PET and coronary CT angiography (CTA).
Twenty nondiabetic patients with AMI (median age, 62 y; 16 men and 4 women) and 7 nondiabetic patients with stable coronary artery disease (CAD; median age, 67 y; 4 men and 3 women) underwent (18)F-FDG PET and coronary CTA 1-6 d after PCS of culprit stenoses. After a low-carbohydrate dietary preparation and more than 12 h of fasting, 480 MBq of (18)F-FDG were injected, and PET images were acquired 3 h later. Helical CTA was performed on a dual-source scanner. Stent position on attenuation-correction noncontrast CT and CTA was used to fuse PET and CTA. Two experienced readers masked to patient data independently quantified maximum target-to-background ratio (maxTBR) at each PCS site. A maxTBR greater than 2.0 was the criterion for significant uptake.
Compared with stable CAD patients, more AMI patients exhibited a PCS site maxTBR greater than 2.0 (12/20 vs. 1/7, P = 0.04). More AMI patients were active smokers (9/20 vs. 0/7 in stable CAD, P = 0.03). After adjusting for baseline demographic differences, stent-myocardium distance, and myocardial (18)F-FDG uptake, presentation of AMI was positively associated with a PCS site maxTBR greater than 2.0 (odds ratio, 31.6; P = 0.044). Prevalence of excess myocardial (18)F-FDG uptake was similar in both populations (8/20 AMI vs. 3/7 stable CAD, P = 0.89).
Systematic fusion of (18)F-FDG PET and coronary CTA demonstrated increased culprit site (18)F-FDG uptake more commonly in patients with AMI than in patients with stable CAD. However, this approach failed to detect increased signal at the culprit site in nearly half of AMI patients, highlighting the challenging nature of in vivo coronary artery plaque metabolic imaging. Nonetheless, our findings suggest that imaging of coronary artery inflammation is feasible, and further work evaluating (18)F-FDG uptake in high-risk coronary plaques prior to rupture would be of great interest.
通过将(18)F-FDG PET 与冠状动脉 CT 血管造影(CTA)进行同机配准,来检测经皮冠状动脉支架置入术(PCI)后急性心肌梗死(AMI)罪犯部位的炎症。
20 名非糖尿病 AMI 患者(中位年龄 62 岁;16 名男性和 4 名女性)和 7 名非糖尿病稳定型 CAD 患者(中位年龄 67 岁;4 名男性和 3 名女性)在 PCI 后 1-6 天行(18)F-FDG PET 和冠状动脉 CTA。在进行低碳水化合物饮食准备和 12 小时以上禁食后,注射 480MBq 的(18)F-FDG,然后在 3 小时后采集 PET 图像。使用双源扫描仪进行螺旋 CTA。在衰减校正非对比 CT 和 CTA 上使用支架位置将 PET 和 CTA 融合。两位经验丰富的读者对患者数据进行了盲法分析,独立对每个 PCI 部位的最大靶标与背景比值(maxTBR)进行了定量分析。maxTBR 大于 2.0 为显著摄取的标准。
与稳定型 CAD 患者相比,更多的 AMI 患者表现出 PCI 部位的 maxTBR 大于 2.0(12/20 比 1/7,P = 0.04)。更多的 AMI 患者为吸烟患者(9/20 比稳定型 CAD 患者的 0/7,P = 0.03)。在校正了基线人口统计学差异、支架心肌距离和心肌(18)F-FDG 摄取后,AMI 的发生与 PCI 部位的 maxTBR 大于 2.0 呈正相关(比值比,31.6;P = 0.044)。在两个人群中,心肌(18)F-FDG 摄取过多的发生率相似(20 例 AMI 中 8 例,7 例稳定型 CAD 中 3 例,P = 0.89)。
通过(18)F-FDG PET 和冠状动脉 CTA 的系统融合,在 AMI 患者中比在稳定型 CAD 患者中更常发现罪犯部位(18)F-FDG 摄取增加。然而,这种方法未能在近一半的 AMI 患者中检测到罪犯部位的信号增加,突出了体内冠状动脉斑块代谢成像的挑战性。尽管如此,我们的发现表明,冠状动脉炎症的成像是可行的,进一步评估高风险冠状动脉斑块破裂前(18)F-FDG 摄取情况将具有很大的意义。